122 related articles for article (PubMed ID: 37793965)
1. CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response.
Nagelli S; Westermarck J
Trends Cancer; 2024 Jan; 10(1):52-64. PubMed ID: 37793965
[TBL] [Abstract][Full Text] [Related]
2. CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis.
Laine A; Nagelli SG; Farrington C; Butt U; Cvrljevic AN; Vainonen JP; Feringa FM; Grönroos TJ; Gautam P; Khan S; Sihto H; Qiao X; Pavic K; Connolly DC; Kronqvist P; Elo LL; Maurer J; Wennerberg K; Medema RH; Joensuu H; Peuhu E; de Visser K; Narla G; Westermarck J
Cancer Res; 2021 Aug; 81(16):4319-4331. PubMed ID: 34145035
[TBL] [Abstract][Full Text] [Related]
3. The CIP2A-TOPBP1 complex safeguards chromosomal stability during mitosis.
De Marco Zompit M; Esteban MT; Mooser C; Adam S; Rossi SE; Jeanrenaud A; Leimbacher PA; Fink D; Shorrocks AK; Blackford AN; Durocher D; Stucki M
Nat Commun; 2022 Jul; 13(1):4143. PubMed ID: 35842428
[TBL] [Abstract][Full Text] [Related]
4. Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity.
Jeong AL; Lee S; Park JS; Han S; Jang CY; Lim JS; Lee MS; Yang Y
J Biol Chem; 2014 Jan; 289(1):28-40. PubMed ID: 24214971
[TBL] [Abstract][Full Text] [Related]
5. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
6. Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1.
Liu H; Qiu H; Song Y; Liu Y; Wang H; Lu M; Deng M; Gu Y; Yin J; Luo K; Zhang Z; Jia X; Zheng G; He Z
Oncogene; 2017 Apr; 36(14):1952-1964. PubMed ID: 27694903
[TBL] [Abstract][Full Text] [Related]
7. Mitotic clustering of pulverized chromosomes from micronuclei.
Lin YF; Hu Q; Mazzagatti A; Valle-Inclán JE; Maurais EG; Dahiya R; Guyer A; Sanders JT; Engel JL; Nguyen G; Bronder D; Bakhoum SF; Cortés-Ciriano I; Ly P
Nature; 2023 Jun; 618(7967):1041-1048. PubMed ID: 37165191
[TBL] [Abstract][Full Text] [Related]
8. The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer.
Adam S; Rossi SE; Moatti N; De Marco Zompit M; Xue Y; Ng TF; Álvarez-Quilón A; Desjardins J; Bhaskaran V; Martino G; Setiaputra D; Noordermeer SM; Ohsumi TK; Hustedt N; Szilard RK; Chaudhary N; Munro M; Veloso A; Melo H; Yin SY; Papp R; Young JTF; Zinda M; Stucki M; Durocher D
Nat Cancer; 2021 Dec; 2(12):1357-1371. PubMed ID: 35121901
[TBL] [Abstract][Full Text] [Related]
9. Oocytes can repair DNA damage during meiosis via a microtubule-dependent recruitment of CIP2A-MDC1-TOPBP1 complex from spindle pole to chromosomes.
Leem J; Kim JS; Oh JS
Nucleic Acids Res; 2023 Jun; 51(10):4899-4913. PubMed ID: 36999590
[TBL] [Abstract][Full Text] [Related]
10. Mitotic tethering enables inheritance of shattered micronuclear chromosomes.
Trivedi P; Steele CD; Au FKC; Alexandrov LB; Cleveland DW
Nature; 2023 Jun; 618(7967):1049-1056. PubMed ID: 37316668
[TBL] [Abstract][Full Text] [Related]
11. CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1.
Kim JS; Kim EJ; Oh JS; Park IC; Hwang SG
Cancer Res; 2013 Nov; 73(22):6667-78. PubMed ID: 23983103
[TBL] [Abstract][Full Text] [Related]
12. Emerging roles of the CIP2A-TopBP1 complex in genome integrity.
Ummethum H; Li J; Lisby M; Oestergaard VH
NAR Cancer; 2023 Dec; 5(4):zcad052. PubMed ID: 37829116
[TBL] [Abstract][Full Text] [Related]
13. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
14. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
[TBL] [Abstract][Full Text] [Related]
15. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
Khanna A; Pimanda JE; Westermarck J
Cancer Res; 2013 Nov; 73(22):6548-53. PubMed ID: 24204027
[TBL] [Abstract][Full Text] [Related]
16. CIP2A facilitates the G1/S cell cycle transition via B-Myb in human papillomavirus 16 oncoprotein E6-expressing cells.
Tian Y; Chen H; Qiao L; Zhang W; Zheng J; Zhao W; Chen JJ; Zhang W
J Cell Mol Med; 2018 Sep; 22(9):4150-4160. PubMed ID: 29893470
[TBL] [Abstract][Full Text] [Related]
17. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
Khanna A; Kauko O; Böckelman C; Laine A; Schreck I; Partanen JI; Szwajda A; Bormann S; Bilgen T; Helenius M; Pokharel YR; Pimanda J; Russel MR; Haglund C; Cole KA; Klefström J; Aittokallio T; Weiss C; Ristimäki A; Visakorpi T; Westermarck J
Cancer Res; 2013 Nov; 73(22):6757-69. PubMed ID: 24072747
[TBL] [Abstract][Full Text] [Related]
18. Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy.
Li S; Feng TT; Guo Y; Yu X; Huang Q; Zhang L; Tang W; Liu Y
Oncol Lett; 2016 Dec; 12(6):5370-5376. PubMed ID: 28101248
[TBL] [Abstract][Full Text] [Related]
19. Exploring the composition of protein-ligand binding sites for cancerous inhibitor of PP2A (CIP2A) by inhibitor guided binding analysis: paving a new way for the Discovery of drug candidates against triple negative breast cancer (TNBC).
Ibitoye O; Ibrahim MAA; Soliman MES
J Recept Signal Transduct Res; 2023 Dec; 43(6):133-143. PubMed ID: 38166612
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
